Mutation of KDM6A Gene in Relapsed Acute Myeloid Leukemia

With the exception of bladder cancer, the frequency of KDM6A gene mutations in malignancy is thought to be rather low in malignant developments. A new study published in Leukemia is suggesting that the loss of KDM6A in patients with acute myeloid leukemia (AML) may provide cells with a selective advantage during chemotherapy, leading to the development of clones with KDM6A mutations or reduced KDM6A expression at the time of relapse. A majority of patients with AML relapse due to intrinsic or acquired drug resistance.

Source: CancerNetwork - July 23, 2019 Category: Cancer & Oncology Authors: John Schieszer Source Type: news